Eli Lilly and Company (NYSE: LLY) recently announced changes to its board of directors. The company elected Jon Moeller as a new member, effective December 1, 2024, while Karen Walker will resign from her position as a member of the board of directors on December 31, 2024. Notably, in 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities.
Mr. Moeller, the chairman of the board, president, and chief executive officer of Procter & Gamble (P&G), brings substantial expertise in driving strategic and operational excellence at scale, having served as an integral part of P&G’s leadership team for over two decades. He will serve on the Lilly Audit Committee and the Directors and Corporate Governance Committee, standing for election by Lilly shareholders at the company’s annual meeting in May 2026.
On the other hand, Ms. Walker has been a member of Lilly’s board since 2018 and has made significant contributions during her tenure, serving as a member of the board’s Audit and Talent and Compensation Committees. She has brought her unique experience in brand-building and go-to-market strategy to the board, providing valuable insight on talent development.
The press release also highlighted Lilly's commitment to turning science into healing to make life better for people around the world. The company has been pioneering life-changing discoveries for nearly 150 years, with its medicines helping tens of millions of people globally. Lilly's scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, including redefining diabetes care, treating obesity, advancing the fight against Alzheimer's disease, providing solutions to debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases.
These changes in the board of directors and the company's commitment to advancing healthcare solutions demonstrate Lilly's ongoing efforts to make a positive impact on global health and well-being. As a result of these announcements, the company's shares have moved 1.9% on the market, and are now trading at a price of $743.51. For the full picture, make sure to review Eli Lilly and's 8-K report.
